David Hoang
Stock Analyst at Citigroup
(2.03)
# 1,268
Out of 4,479 analysts
24
Total ratings
42.86%
Success rate
-4.55%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $172 → $176 | $154.75 | +13.73% | 4 | Jun 26, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $29.44 | +63.04% | 1 | Jun 21, 2024 | |
| SAGE Sage Therapeutics | Initiates: Sell | $8 | $10.77 | -25.72% | 1 | May 29, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $62 → $60 | $36.70 | +63.49% | 2 | May 10, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $30 | $15.93 | +88.32% | 3 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $127 → $125 | $80.48 | +55.32% | 3 | May 7, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $140 → $150 | $138.13 | +8.59% | 3 | May 3, 2024 | |
| SLDB Solid Biosciences | Initiates: Buy | $16 | $6.03 | +165.34% | 1 | Mar 15, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $16 | $7.65 | +109.15% | 1 | Mar 7, 2024 | |
| LBPH Longboard Pharmaceuticals | Initiates: Buy | $40 | $31.26 | +27.96% | 1 | Feb 16, 2024 | |
| DNLI Denali Therapeutics | Initiates: Buy | $32 | $21.67 | +47.67% | 1 | Dec 13, 2023 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Neutral | $220 | $249.30 | -11.75% | 1 | Apr 26, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | $80 | $25.29 | +216.33% | 1 | Apr 26, 2023 | |
| GOSS Gossamer Bio | Downgrades: Neutral | $3 | $0.94 | +219.22% | 1 | Dec 7, 2022 |
Sarepta Therapeutics
Jun 26, 2024
Downgrades: Neutral
Price Target: $172 → $176
Current: $154.75
Upside: +13.73%
Harmony Biosciences Holdings
Jun 21, 2024
Initiates: Buy
Price Target: $48
Current: $29.44
Upside: +63.04%
Sage Therapeutics
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $10.77
Upside: -25.72%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Buy
Price Target: $62 → $60
Current: $36.70
Upside: +63.49%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $30 → $30
Current: $15.93
Upside: +88.32%
Axsome Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $127 → $125
Current: $80.48
Upside: +55.32%
Neurocrine Biosciences
May 3, 2024
Maintains: Neutral
Price Target: $140 → $150
Current: $138.13
Upside: +8.59%
Solid Biosciences
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $6.03
Upside: +165.34%
Voyager Therapeutics
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $7.65
Upside: +109.15%
Longboard Pharmaceuticals
Feb 16, 2024
Initiates: Buy
Price Target: $40
Current: $31.26
Upside: +27.96%
Denali Therapeutics
Dec 13, 2023
Initiates: Buy
Price Target: $32
Current: $21.67
Upside: +47.67%
Alnylam Pharmaceuticals
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $249.30
Upside: -11.75%
Arrowhead Pharmaceuticals
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $25.29
Upside: +216.33%
Gossamer Bio
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.94
Upside: +219.22%